Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 186 articles: HTML format

Single Articles

May 2024
1. SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al
   Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
   Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850.
   PubMed     Abstract available
   
   
   April 2024
2. COULBORN RM, Danet C, Alsalhani A
   Measles and rubella vaccine microneedle patch: new hope to reach the unreached children.
   Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749.
   PubMed    
   
   
   
3. ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al
   A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
   Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532.
   PubMed     Abstract available
   
   
   
4. ADEPOJU P
   Moderna stalls on African vaccine manufacturing plans.
   Lancet. 2024;403:1617.
   PubMed    
   
   
   
5. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
   Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
   Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
   PubMed     Abstract available
   
   
   
6. DAUBENBERGER CA, Silva JC
   First-generation malaria vaccine successfully implemented in three African countries.
   Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
   PubMed    
   
   
   March 2024
7. RAQIB R
   Bivalent conjugate vaccines for typhoid and paratyphoid fever.
   Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
   PubMed    
   
   
   
8. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
   The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
   Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
   PubMed     Abstract available
   
   
   
9. BURKI T
   Pivotal tuberculosis vaccine trial begins.
   Lancet. 2024;403:1125.
   PubMed    
   
   
   
10. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    PubMed    
    
    
    
11. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    PubMed    
    
    
    
12. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    PubMed     Abstract available
    
    
    February 2024
13. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    PubMed     Abstract available
    
    
    
14. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    PubMed    
    
    
    
15. ABRAVANEL F, Lhomme S
    Hecolin vaccine: long-term efficacy against HEV for a three-dose regimen.
    Lancet. 2024 Feb 19:S0140-6736(23)02455-8. doi: 10.1016/S0140-6736(23)02455.
    PubMed    
    
    
    
16. HUANG S, Zhang X, Su Y, Zhuang C, et al
    Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2024 Feb 19:S0140-6736(23)02234-1. doi: 10.1016/S0140-6736(23)02234.
    PubMed     Abstract available
    
    
    
17. CARPIANO RM, Callahan T, Elharake JA, Hotez P, et al
    Vaccination and the defence of democracy - Authors' reply.
    Lancet. 2024;403:529-530.
    PubMed    
    
    
    
18. ALBIN RL
    Vaccination and the defence of democracy.
    Lancet. 2024;403:529.
    PubMed    
    
    
    
19. DOPPEN M, Kearns C, Hills T, Weatherall M, et al
    Intramuscular vaccination needle length: a call to arms.
    Lancet. 2024;403:528-529.
    PubMed    
    
    
    
20. NNAJI CA, Amaechi UA, Wiysonge CS
    R21/Matrix-M vaccine: optimising supply, maximising impact.
    Lancet. 2024;403:525.
    PubMed    
    
    
    
21. THE LANCET
    Malaria vaccines: a test for global health.
    Lancet. 2024;403:503.
    PubMed    
    
    
    
22. ADEPOJU P
    Routine malaria vaccinations begin.
    Lancet. 2024;403:423.
    PubMed    
    
    
    
23. MOORTHY V, Hamel MJ, Smith PG
    Malaria vaccines for children: and now there are two.
    Lancet. 2024 Feb 1:S0140-6736(23)02743-5. doi: 10.1016/S0140-6736(23)02743.
    PubMed    
    
    
    
24. DATOO MS, Dicko A, Tinto H, Ouedraogo JB, et al
    Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
    Lancet. 2024 Feb 1:S0140-6736(23)02511-4. doi: 10.1016/S0140-6736(23)02511.
    PubMed     Abstract available
    
    
    January 2024
25. PATEL PD, Liang Y, Meiring JE, Chasweka N, et al
    Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
    Lancet. 2024 Jan 25:S0140-6736(23)02031-7. doi: 10.1016/S0140-6736(23)02031.
    PubMed     Abstract available
    
    
    
26. TADESSE BT, Cardona RSB, Marks F
    Long-term protection conferred by typhoid conjugate vaccines: a step towards typhoid elimination?
    Lancet. 2024 Jan 25:S0140-6736(23)02350-4. doi: 10.1016/S0140-6736(23)02350.
    PubMed    
    
    
    
27. TERAI M, Sato T
    Individualised neoantigen cancer vaccine therapy.
    Lancet. 2024 Jan 18:S0140-6736(23)02463-7. doi: 10.1016/S0140-6736(23)02463.
    PubMed    
    
    
    
28. ALVES L
    Brazil to start widespread dengue vaccinations.
    Lancet. 2024;403:133.
    PubMed    
    
    
    
29. GULLIFORD MC, Steves CJ
    Access to COVID-19 vaccination and COVID-19-related hospital admissions and mortality.
    Lancet. 2024 Jan 12:S0140-6736(23)02622-3. doi: 10.1016/S0140-6736(23)02622.
    PubMed    
    
    
    
30. 
    Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2024 Jan 12:S0140-6736(23)02467-4. doi: 10.1016/S0140-6736(23)02467.
    PubMed     Abstract available
    
    
    December 2023
31. THUMBI SM, Blumberg L, le Roux K, Salahuddin N, et al
    A call to accelerate an end to human rabies deaths.
    Lancet. 2023;400:2261-2264.
    PubMed    
    
    
    
32. KARIM SSA, Sikazwe I
    Building on Pasteur's legacy: producing vaccines in Africa.
    Lancet. 2023;400:2164-2166.
    PubMed    
    
    
    November 2023
33. KANG G
    Success from the South: the rotavirus vaccine story and its lessons.
    Lancet. 2023 Nov 28:S0140-6736(23)02520-5. doi: 10.1016/S0140-6736(23)02520.
    PubMed    
    
    
    
34. ADEPOJU P
    Nigeria targets almost 8 million girls with HPV vaccine.
    Lancet. 2023;402:1612.
    PubMed    
    
    
    
35. DU Z, Wang L, Bai Y, Pei Y, et al
    Mitigation of respiratory syncytial virus epidemics by RSVpreF vaccines after the COVID-19 pandemic in the UK: a modelling study.
    Lancet. 2023;402 Suppl 1:S39.
    PubMed     Abstract available
    
    
    October 2023
36. MEMISH ZA, Blumberg L, Al-Maani AS, Baru R, et al
    Moving cholera vaccines ahead of the epidemic curve.
    Lancet. 2023 Oct 17:S0140-6736(23)02244-4. doi: 10.1016/S0140-6736(23)02244.
    PubMed    
    
    
    
37. ADEPOJU P
    Malaria community welcomes WHO vaccine approval.
    Lancet. 2023;402:1316.
    PubMed    
    
    
    September 2023
38. YANG C, Lapp L, Tebbutt SJ
    Overcoming COVID-19 vaccine hesitancy hurdles.
    Lancet. 2023;402:1129-1130.
    PubMed    
    
    
    
39. AARS OK, Schwalbe N
    Bold moves for vaccine manufacturing equity.
    Lancet. 2023;402:771-772.
    PubMed    
    
    
    August 2023
40. DAI L, Duan H, Liu X, Zhou H, et al
    Omicron neutralisation: RBD-dimer booster versus BF.7 and BA.5.2 breakthrough infection.
    Lancet. 2023;402:687-689.
    PubMed    
    
    
    
41. SINHA P, Mehta S
    Food: the tuberculosis vaccine we already have.
    Lancet. 2023 Aug 8:S0140-6736(23)01321-1. doi: 10.1016/S0140-6736(23)01321.
    PubMed    
    
    
    July 2023
42. AGUS DB, Nguyen A, Bell J
    Successful adult vaccine drives must centre disability inclusion - Authors' reply.
    Lancet. 2023;402:370.
    PubMed    
    
    
    
43. ROTENBERG S, Downer M
    Successful adult vaccine drives must centre disability inclusion.
    Lancet. 2023;402:369-370.
    PubMed    
    
    
    
44. ZHOU J, Zhang Y, Mo K, Newbert H, et al
    mRNA vaccines do not stop with COVID-19.
    Lancet. 2023 Jul 27:S0140-6736(23)01514-3. doi: 10.1016/S0140-6736(23)01514.
    PubMed    
    
    
    
45. SAIED AA
    Building Africa's first mRNA vaccine facility.
    Lancet. 2023;402:287-288.
    PubMed    
    
    
    
46. DEVI S
    12 countries to get first doses of malaria vaccine.
    Lancet. 2023;402:172.
    PubMed    
    
    
    June 2023
47. SCHNEIDER M, Narciso-Abraham M, Hadl S, McMahon R, et al
    Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 12:S0140-6736(23)00641-4. doi: 10.1016/S0140-6736(23)00641.
    PubMed     Abstract available
    
    
    
48. STEPHENSON KE
    Live-attenuated Chikungunya vaccine: a possible new era.
    Lancet. 2023 Jun 12:S0140-6736(23)01170-4. doi: 10.1016/S0140-6736(23)01170.
    PubMed    
    
    
    May 2023
49. MFINANGA SG, Gatei W, Tinuga F, Mwengee WMP, et al
    Tanzania's COVID-19 vaccination strategy: lessons, learning, and execution.
    Lancet. 2023;401:1649.
    PubMed    
    
    
    
50. ZAROCOSTAS J
    Gavi unveils malaria vaccine plans.
    Lancet. 2023;401:1485.
    PubMed    
    
    
    April 2023
51. ALOMARI O
    Why vaccinations should be a top priority in earthquake relief efforts.
    Lancet. 2023;401:1263-1264.
    PubMed    
    
    
    March 2023
52. OKOKHERE PO
    Finding a safe and effective vaccine for the Lassa virus.
    Lancet. 2023 Mar 16:S0140-6736(23)00093-4. doi: 10.1016/S0140-6736(23)00093.
    PubMed    
    
    
    
53. TSCHISMAROV R, Van Damme P, Germain C, De Coster I, et al
    Immunogenicity, safety, and tolerability of a recombinant measles-vectored Lassa fever vaccine: a randomised, placebo-controlled, first-in-human trial.
    Lancet. 2023 Mar 16:S0140-6736(23)00048-X. doi: 10.1016/S0140-6736(23)00048.
    PubMed     Abstract available
    
    
    
54. KEECH C, Miller VE, Rizzardi B, Hoyle C, et al
    Immunogenicity and safety of BPZE1, an intranasal live attenuated pertussis vaccine, versus tetanus-diphtheria-acellular pertussis vaccine: a randomised, double-blind, phase 2b trial.
    Lancet. 2023;401:843-855.
    PubMed     Abstract available
    
    
    
55. EDWARDS KM, Decker MD
    An alternative route to pertussis protection?
    Lancet. 2023;401:800-801.
    PubMed    
    
    
    
56. STOCKWELL M
    Effect of a nationwide intervention of electronic letters with behavioural nudges on influenza vaccination in older adults in Denmark.
    Lancet. 2023 Mar 3:S0140-6736(23)00453-1. doi: 10.1016/S0140-6736(23)00453.
    PubMed    
    
    
    
57. JOHANSEN ND, Vaduganathan M, Bhatt AS, Lee SG, et al
    Electronic nudges to increase influenza vaccination uptake in Denmark: a nationwide, pragmatic, registry-based, randomised implementation trial.
    Lancet. 2023 Mar 3:S0140-6736(23)00349-5. doi: 10.1016/S0140-6736(23)00349.
    PubMed     Abstract available
    
    
    
58. CARPIANO RM, Callaghan T, DiResta R, Brewer NT, et al
    Confronting the evolution and expansion of anti-vaccine activism in the USA in the COVID-19 era.
    Lancet. 2023 Mar 2:S0140-6736(23)00136-8. doi: 10.1016/S0140-6736(23)00136.
    PubMed    
    
    
    January 2023
59. HAMER MJ, Houser KV, Hofstetter AR, Ortega-Villa AM, et al
    Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial.
    Lancet. 2023;401:294-302.
    PubMed     Abstract available
    
    
    
60. MANNO D
    Developing a vaccine against Marburg virus disease.
    Lancet. 2023;401:251-253.
    PubMed    
    
    
    
61. ELLINGTON S, Jatlaoui TC
    COVID-19 vaccination is effective at preventing severe illness and complications during pregnancy.
    Lancet. 2023 Jan 17:S0140-6736(22)02613-7. doi: 10.1016/S0140-6736(22)02613.
    PubMed    
    
    
    
62. VILLAR J, Soto Conti CP, Gunier RB, Ariff S, et al
    Pregnancy outcomes and vaccine effectiveness during the period of omicron as the variant of concern, INTERCOVID-2022: a multinational, observational study.
    Lancet. 2023 Jan 17:S0140-6736(22)02467-9. doi: 10.1016/S0140-6736(22)02467.
    PubMed     Abstract available
    
    
    December 2022
63. BUTLER CC, Hobbs FDR, Gbinigie OA, Rahman NM, et al
    Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
    Lancet. 2022 Dec 22:S0140-6736(22)02597-1. doi: 10.1016/S0140-6736(22)02597.
    PubMed     Abstract available
    
    
    
64. ZAMAN K, Bandyopadhyay AS, Hoque M, Gast C, et al
    Evaluation of the safety, immunogenicity, and faecal shedding of novel oral polio vaccine type 2 in healthy newborn infants in Bangladesh: a randomised, controlled, phase 2 clinical trial.
    Lancet. 2022 Dec 7:S0140-6736(22)02397-2. doi: 10.1016/S0140-6736(22)02397.
    PubMed     Abstract available
    
    
    
65. NANQUE LM, Fisker AB
    Maximising the lessons learned from trial data after emergency use listing of a novel oral polio vaccine.
    Lancet. 2022 Dec 7:S0140-6736(22)02455-2. doi: 10.1016/S0140-6736(22)02455.
    PubMed    
    
    
    November 2022
66. JACKSON S, Kabir Z, Comiskey C
    Impact of universal tuberculosis vaccination cessation on the epidemiology of paediatric tuberculosis cases in Ireland from 2011 to 2021.
    Lancet. 2022;400 Suppl 1:S53.
    PubMed     Abstract available
    
    
    
67. ISBA R, Brennan L, Davies N, Knight J, et al
    Measles, mumps, and rubella vaccination coverage in children younger than 5 years attending a paediatric emergency department in Manchester, UK: a cross-sectional observational study.
    Lancet. 2022;400 Suppl 1:S51.
    PubMed     Abstract available
    
    
    
68. BURNS R, Campos-Matos I, Harron K, Aldridge RW, et al
    COVID-19 vaccination uptake for half a million non-EU migrants and refugees in England: a linked retrospective population-based cohort study.
    Lancet. 2022;400 Suppl 1:S5.
    PubMed     Abstract available
    
    
    
69. HUF SW, Woldmann L, Crespo RF, Grailey K, et al
    Implementing behavioural science informed letter interventions to increase COVID-19 vaccination uptake in uncontactable London residents: a difference-in-difference study in London, UK.
    Lancet. 2022;400 Suppl 1:S41.
    PubMed     Abstract available
    
    
    October 2022
70. KLAPSA D, Wilton T, Zealand A, Bujaki E, et al
    Sustained detection of type 2 poliovirus in London sewage between February and July, 2022, by enhanced environmental surveillance.
    Lancet. 2022;400:1531-1538.
    PubMed     Abstract available
    
    
    
71. HILL M, Pollard AJ
    Detection of poliovirus in London highlights the value of sewage surveillance.
    Lancet. 2022;400:1491-1492.
    PubMed    
    
    
    
72. AGUS DB, Nguyen A, Sall AA, Bell J, et al
    COVID-19 and other adult vaccines can drive global disease prevention.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02084.
    PubMed    
    
    
    
73. OPEL DJ, Brewer NT, Buttenheim AM, Callaghan T, et al
    The legacy of the COVID-19 pandemic for childhood vaccination in the USA.
    Lancet. 2022 Oct 26. pii: S0140-6736(22)01693.
    PubMed    
    
    
    
74. AGRAWAL U, Bedston S, McCowan C, Oke J, et al
    Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales.
    Lancet. 2022;400:1305-1320.
    PubMed     Abstract available
    
    
    
75. MSELLATI P, Sow K, Desclaux A, Cottrell G, et al
    Reconsidering the COVID-19 vaccine strategy in West and Central Africa.
    Lancet. 2022;400:1304.
    PubMed    
    
    
    September 2022
76. HAMEED SS, Hall E, Grange Z, Sullivan C, et al
    Characterising adults in Scotland who are not vaccinated against COVID-19.
    Lancet. 2022;400:993-995.
    PubMed    
    
    
    
77. ZIEGLER T, Moen A, Zhang W, Cox NJ, et al
    Global Influenza Surveillance and Response System: 70 years of responding to the expected and preparing for the unexpected.
    Lancet. 2022;400:981-982.
    PubMed    
    
    
    August 2022
78. UYEKI TM, Hui DS, Zambon M, Wentworth DE, et al
    Influenza.
    Lancet. 2022;400:693-706.
    PubMed     Abstract available
    
    
    
79. HILL M, Bandyopadhyay AS, Pollard AJ
    Emergence of vaccine-derived poliovirus in high-income settings in the absence of oral polio vaccine use.
    Lancet. 2022 Aug 18. pii: S0140-6736(22)01582.
    PubMed    
    
    
    July 2022
80. DURRHEIM DN
    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.
    PubMed    
    
    
    
81. MELLO MM, Opel DJ, Benjamin RM, Callaghan T, et al
    Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA.
    Lancet. 2022 Jul 8. pii: S0140-6736(22)00875.
    PubMed    
    
    
    June 2022
82. SACCO C, Del Manso M, Mateo-Urdiales A, Rota MC, et al
    Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01185.
    PubMed     Abstract available
    
    
    
83. LADHANI SN
    COVID-19 vaccination for children aged 5-11 years.
    Lancet. 2022 Jun 30. pii: S0140-6736(22)01245.
    PubMed    
    
    
    
84. LI G, Cappuccini F, Marchevsky NG, Aley PK, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
    Lancet. 2022;399:2212-2225.
    PubMed     Abstract available
    
    
    
85. WONG HL, Hu M, Zhou CK, Lloyd PC, et al
    Risk of myocarditis and pericarditis after the COVID-19 mRNA vaccination in the USA: a cohort study in claims databases.
    Lancet. 2022;399:2191-2199.
    PubMed     Abstract available
    
    
    
86. PATEL M, Patel M
    Increasing children's global access to COVID-19 vaccines.
    Lancet. 2022;399:2171-2173.
    PubMed    
    
    
    
87. HUSBY A, Kober L
    COVID-19 mRNA vaccination and myocarditis or pericarditis.
    Lancet. 2022;399:2168-2169.
    PubMed    
    
    
    May 2022
88. SASIENI P, Castanon A
    HPV vaccination and cervical cancer screening - Authors' reply.
    Lancet. 2022;399:1940.
    PubMed    
    
    
    
89. BEWLEY S
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939.
    PubMed    
    
    
    
90. KAMAMOTO S, Murayama A, Hamaki T, Kusumi E, et al
    HPV vaccination and cervical cancer screening.
    Lancet. 2022;399:1939-1940.
    PubMed    
    
    
    
91. COUSINS S
    Eliminating cholera in Haiti.
    Lancet. 2022;399:1928-1929.
    PubMed    
    
    
    
92. DZAU VJ, Balatbat CA, Offodile AC 2nd
    Closing the global vaccine equity gap: equitably distributed manufacturing.
    Lancet. 2022 May 6. pii: S0140-6736(22)00793.
    PubMed    
    
    
    April 2022
93. ADEPOJU P
    Africa CDC warns COVID-19 vaccine production could cease.
    Lancet. 2022;399:1683.
    PubMed    
    
    
    
94. NGUYEN-TRAN H, Messacar K
    Preventing enterovirus A71 disease: another promising vaccine for children.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00380.
    PubMed    
    
    
    
95. NGUYEN TT, Chiu CH, Lin CY, Chiu NC, et al
    Efficacy, safety, and immunogenicity of an inactivated, adjuvanted enterovirus 71 vaccine in infants and children: a multiregion, double-blind, randomised, placebo-controlled, phase 3 trial.
    Lancet. 2022 Apr 12. pii: S0140-6736(22)00313.
    PubMed     Abstract available
    
    
    
96. BUCHBINDER SP, McElrath MJ, Dieffenbach C, Corey L, et al
    COVID-19 vaccination and HIV-1 acquisition - Authors' reply.
    Lancet. 2022;399:e36.
    PubMed    
    
    
    
97. LOGUNOV DY, Livermore DM, Ornelles DA, Bayer W, et al
    COVID-19 vaccination and HIV-1 acquisition.
    Lancet. 2022;399:e34-e35.
    PubMed    
    
    
    
98. MENNI C, Valdes AM, Polidori L, Antonelli M, et al
    Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study.
    Lancet. 2022 Apr 7. pii: S0140-6736(22)00327.
    PubMed     Abstract available
    
    
    
99. WINTER AK, Moss WJ
    Rubella.
    Lancet. 2022;399:1336-1346.
    PubMed     Abstract available
    
    
    
100. KHOBRAGADE A, Bhate S, Ramaiah V, Deshpande S, et al
     Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India.
     Lancet. 2022;399:1313-1321.
     PubMed     Abstract available
     
     
     
101. BLAKNEY AK, Bekker LG
     DNA vaccines join the fight against COVID-19.
     Lancet. 2022;399:1281-1282.
     PubMed    
     
     
     March 2022
102. KRAUSE PR, Rees H, Figueroa JP, Swaminathan S, et al
     Booster vaccines for COVID-19 vaccine breakthrough cases? - Authors' reply.
     Lancet. 2022;399:1225.
     PubMed    
     
     
     
103. NIXON DF, Schwartz RE, Ndhlovu LC
     Booster vaccines for COVID-19 vaccine breakthrough cases?
     Lancet. 2022;399:1224.
     PubMed    
     
     
     
104. BEKKER LG, Garrett N, Goga A, Fairall L, et al
     Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study.
     Lancet. 2022;399:1141-1153.
     PubMed     Abstract available
     
     
     
105. USHER AD
     CEPI launches 100-day vaccine "moonshot".
     Lancet. 2022;399:1107-1108.
     PubMed    
     
     
     
106. REARTE A, Castelli JM, Rearte R, Fuentes N, et al
     Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study.
     Lancet. 2022 Mar 15. pii: S0140-6736(22)00011.
     PubMed     Abstract available
     
     
     
107. MILLS EJ, Reis G
     Evaluating COVID-19 vaccines in the real world.
     Lancet. 2022 Mar 15. pii: S0140-6736(22)00194.
     PubMed    
     
     
     
108. MANCA T, Baylis F, Munoz FM, Top KA, et al
     Prioritise research on vaccines for pregnant and breastfeeding women.
     Lancet. 2022;399:890-893.
     PubMed    
     
     
     
109. FALLAH MP, Reinhart E
     Apartheid logic in global health.
     Lancet. 2022;399:902-903.
     PubMed    
     
     
     
110. NUNEZ I
     Vaccine approval before phase 3 trial results: a consequence of vaccine access inequity.
     Lancet. 2022 Mar 2. pii: S0140-6736(22)00164.
     PubMed    
     
     
     February 2022
111. CHEMAITELLY H, Abu-Raddad LJ
     Waning effectiveness of COVID-19 vaccines.
     Lancet. 2022;399:771-773.
     PubMed    
     
     
     
112. 
     Variation in the COVID-19 infection-fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis.
     Lancet. 2022 Feb 24. pii: S0140-6736(21)02867.
     PubMed     Abstract available
     
     
     
113. BAJAJ SS, Maki L, Stanford FC
     Vaccine apartheid: global cooperation and equity.
     Lancet. 2022 Feb 23. pii: S0140-6736(22)00328.
     PubMed    
     
     
     
114. PIECHOTTA V, Harder T
     Waning of COVID-19 vaccine effectiveness: individual and public health risk.
     Lancet. 2022 Feb 21. pii: S0140-6736(22)00282.
     PubMed    
     
     
     
115. FEIKIN DR, Higdon MM, Abu-Raddad LJ, Andrews N, et al
     Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression.
     Lancet. 2022 Feb 21. pii: S0140-6736(22)00152.
     PubMed     Abstract available
     
     
     
116. KALAFAT E, Magee LA, von Dadelszen P, Heath P, et al
     COVID-19 booster doses in pregnancy and global vaccine equity.
     Lancet. 2022 Feb 18. pii: S0140-6736(22)00166.
     PubMed    
     
     
     
117. MADHI SA, Ihekweazu C, Rees H, Pollard AJ, et al
     Decoupling of omicron variant infections and severe COVID-19.
     Lancet. 2022 Feb 18. pii: S0140-6736(22)00109.
     PubMed    
     
     
     
118. EGGER S, Egger G
     The vaccinated propor-tion of people with COVID-19 needs context.
     Lancet. 2022;399:627.
     PubMed    
     
     
     
119. CAPLAN AL
     Stigma, vaccination, and moral accountability.
     Lancet. 2022;399:626-627.
     PubMed    
     
     
     
120. SAMARASEKERA U
     Ayoade Alakija: advancing equity in the COVID-19 response.
     Lancet. 2022;399:511.
     PubMed    
     
     
     
121. BURKI T
     Fresh questions over Gates Foundation governance.
     Lancet. 2022;399:508.
     PubMed    
     
     
     
122. BEYRER C
     Archbishop Desmond Tutu and the universality of health and human rights.
     Lancet. 2022;399:503-504.
     PubMed    
     
     
     
123. NORDSTROM P, Ballin M, Nordstrom A
     Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden.
     Lancet. 2022 Feb 4. pii: S0140-6736(22)00089.
     PubMed     Abstract available
     
     
     
124. KARAFILLAKIS E, Van Damme P, Hendrickx G, Larson HJ, et al
     COVID-19 in Europe: new challenges for addressing vaccine hesitancy.
     Lancet. 2022 Feb 3. pii: S0140-6736(22)00150.
     PubMed    
     
     
     
125. 
     Pandemic preparedness and COVID-19: an exploratory analysis of infection and fatality rates, and contextual factors associated with preparedness in 177 countries, from Jan 1, 2020, to Sept 30, 2021.
     Lancet. 2022 Feb 1. pii: S0140-6736(22)00172.
     PubMed     Abstract available
     
     
     January 2022
126. JAFFE S
     The next steps for US vaccine mandates.
     Lancet. 2022;399:425-426.
     PubMed    
     
     
     
127. 
     Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial.
     Lancet. 2022 Jan 27. pii: S0140-6736(22)00101.
     PubMed     Abstract available
     
     
     
128. HUBSCHEN JM, Gouandjika-Vasilache I, Dina J
     Measles.
     Lancet. 2022 Jan 27. pii: S0140-6736(21)02004.
     PubMed     Abstract available
     
     
     
129. FENDLER A, Shepherd STC, Au L, Wu M, et al
     Omicron neutralising antibodies after third COVID-19 vaccine dose in patients with cancer.
     Lancet. 2022 Jan 25. pii: S0140-6736(22)00147.
     PubMed    
     
     
     
130. LANE R
     Jamal Rifi: family doctor building bridges in the community.
     Lancet. 2022;399:353.
     PubMed    
     
     
     
131. COSTA CLEMENS SA, Weckx L, Clemens R, Almeida Mendes AV, et al
     Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
     Lancet. 2022 Jan 21. pii: S0140-6736(22)00094.
     PubMed     Abstract available
     
     
     
132. BRAVO L, Smolenov I, Han HH, Li P, et al
     Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
     Lancet. 2022 Jan 20. pii: S0140-6736(22)00055.
     PubMed     Abstract available
     
     
     
133. VESIKARI T
     Trimeric S protein COVID-19 vaccine needs to find its place.
     Lancet. 2022 Jan 20. pii: S0140-6736(22)00096.
     PubMed    
     
     
     
134. CARR EJ, Wu M, Harvey R, Billany RE, et al
     Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients.
     Lancet. 2022 Jan 20. pii: S0140-6736(22)00104.
     PubMed    
     
     
     
135. WU M, Wall EC, Carr EJ, Harvey R, et al
     Three-dose vaccination elicits neutralising antibodies against omicron.
     Lancet. 2022 Jan 19. pii: S0140-6736(22)00092.
     PubMed    
     
     
     
136. KUHLMANN C, Mayer CK, Claassen M, Maponga T, et al
     Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
     Lancet. 2022 Jan 18. pii: S0140-6736(22)00090.
     PubMed    
     
     
     December 2021
137. KING J, Ferraz OLM, Jones A
     Mandatory COVID-19 vaccination and human rights.
     Lancet. 2021 Dec 23. pii: S0140-6736(21)02873.
     PubMed    
     
     
     
138. HALPERIN SA, Ye L, MacKinnon-Cameron D, Smith B, et al
     Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-
     Lancet. 2021 Dec 23. pii: S0140-6736(21)02753.
     PubMed     Abstract available
     
     
     
139. KENNEDY RB
     Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine.
     Lancet. 2021 Dec 23. pii: S0140-6736(21)02834.
     PubMed    
     
     
     
140. LEUNG K, Wu JT
     Managing waning vaccine protection against SARS-CoV-2 variants.
     Lancet. 2021 Dec 20. pii: S0140-6736(21)02841.
     PubMed    
     
     
     
141. KATIKIREDDI SV, Cerqueira-Silva T, Vasileiou E, Robertson C, et al
     Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil.
     Lancet. 2021 Dec 20. pii: S0140-6736(21)02754.
     PubMed     Abstract available
     
     
     
142. PEELING RW, Heymann DL, Teo YY, Garcia PJ, et al
     Diagnostics for COVID-19: moving from pandemic response to control.
     Lancet. 2021 Dec 20. pii: S0140-6736(21)02346.
     PubMed     Abstract available
     
     
     
143. MCINTYRE PB, Aggarwal R, Jani I, Jawad J, et al
     COVID-19 vaccine strategies must focus on severe disease and global equity.
     Lancet. 2021 Dec 16. pii: S0140-6736(21)02835.
     PubMed    
     
     
     
144. STUART ASV, Shaw RH, Liu X, Greenland M, et al
     Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.
     Lancet. 2021 Dec 6. pii: S0140-6736(21)02718.
     PubMed     Abstract available
     
     
     
145. RICHARDSON CD
     Mixing mRNA, adenoviral, and spike-adjuvant vaccines for protection against COVID-19.
     Lancet. 2021 Dec 6. pii: S0140-6736(21)02757.
     PubMed    
     
     
     
146. KARIM SSA, Karim QA
     Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic.
     Lancet. 2021 Dec 3. pii: S0140-6736(21)02758.
     PubMed    
     
     
     
147. MENDELSON M, Venter F, Moshabela M, Gray G, et al
     The political theatre of the UK's travel ban on South Africa.
     Lancet. 2021 Dec 3. pii: S0140-6736(21)02752.
     PubMed    
     
     
     
148. MUNRO APS, Janani L, Cornelius V, Aley PK, et al
     Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial.
     Lancet. 2021 Dec 2. pii: S0140-6736(21)02717.
     PubMed     Abstract available
     
     
     November 2021
149. JAFFE S
     Legal challenges threaten Biden's COVID-19 vaccine rule.
     Lancet. 2021;398:1863-1864.
     PubMed    
     
     
     
150. BURKI T
     mRNA discoveries earn the 2021 Prince Mahidol Award.
     Lancet. 2021;398:1865.
     PubMed    
     
     
     
151. OMER SB, Benjamin RM, Brewer NT, Buttenheim AM, et al
     Promoting COVID-19 vaccine acceptance: recommendations from the Lancet Commission on Vaccine Refusal, Acceptance, and Demand in the USA.
     Lancet. 2021 Nov 15. pii: S0140-6736(21)02507.
     PubMed     Abstract available
     
     
     
152. PAVORD S, Scully M, Lester W, Makris M, et al
     Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine?
     Lancet. 2021;398:1801.
     PubMed    
     
     
     
153. BHUYAN P, Medin J, da Silva HG, Yadavalli M, et al
     Just how common is TTS after a second dose of the ChAdOx1 nCov-19 vaccine? - Authors' reply.
     Lancet. 2021;398:1801-1802.
     PubMed    
     
     
     
154. LAZARUS R, Baos S, Cappel-Porter H, Carson-Stevens A, et al
     Safety and immunogenicity of concomitant administration of COVID-19 vaccines (ChAdOx1 or BNT162b2) with seasonal influenza vaccines in adults in the UK (ComFluCOV): a multicentre, randomised, controlled, phase 4 trial.
     Lancet. 2021 Nov 11. pii: S0140-6736(21)02329.
     PubMed     Abstract available
     
     
     
155. ELLA R, Reddy S, Blackwelder W, Potdar V, et al
     Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial.
     Lancet. 2021 Nov 11. pii: S0140-6736(21)02000.
     PubMed     Abstract available
     
     
     
156. LI JX, Zhu FC
     Inactivated SARS-CoV-2 vaccine (BBV152)-induced protection against symptomatic COVID-19.
     Lancet. 2021 Nov 11. pii: S0140-6736(21)02014.
     PubMed    
     
     
     
157. ALVES L
     Health experts welcome Brazil COVID-19 inquiry findings.
     Lancet. 2021;398:1674-1675.
     PubMed    
     
     
     
158. USHER AD
     New budget and strategy for ACT-A.
     Lancet. 2021;398:1677.
     PubMed    
     
     
     
159. ZAROCOSTAS J
     WHO's Tedros set to be re-elected unopposed.
     Lancet. 2021;398:1676.
     PubMed    
     
     
     
160. ORTIZ JR, Neuzil KM
     The value of vaccine programme impact monitoring during the COVID-19 pandemic.
     Lancet. 2021 Nov 3. pii: S0140-6736(21)02322.
     PubMed    
     
     
     
161. MCNAMARA LA, Wiegand RE, Burke RM, Sharma AJ, et al
     Estimating the early impact of the US COVID-19 vaccination programme on COVID-19 cases, emergency department visits, hospital admissions, and deaths among adults aged 65 years and older: an ecological analysis of national surveillance data.
     Lancet. 2021 Nov 3. pii: S0140-6736(21)02226.
     PubMed     Abstract available
     
     
     
162. FALCARO M, Castanon A, Ndlela B, Checchi M, et al
     The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register-based observational study.
     Lancet. 2021 Nov 3. pii: S0140-6736(21)02178.
     PubMed     Abstract available
     
     
     October 2021
163. HODGES S, Hornberger J, Kufakurinani U, Rudra S, et al
     When suspicion replaces evidence in public health.
     Lancet. 2021;398:1565-1566.
     PubMed    
     
     
     
164. BARDA N, Dagan N, Cohen C, Hernan MA, et al
     Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study.
     Lancet. 2021 Oct 29. pii: S0140-6736(21)02249.
     PubMed     Abstract available
     
     
     
165. GRANGE Z, Buelo A, Sullivan C, Moore E, et al
     Characteristics and risk of COVID-19-related death in fully vaccinated people in Scotland.
     Lancet. 2021 Oct 28. pii: S0140-6736(21)02316.
     PubMed    
     
     
     
166. SONABEND R, Whittles LK, Imai N, Perez-Guzman PN, et al
     Non-pharmaceutical interventions, vaccination, and the SARS-CoV-2 delta variant in England: a mathematical modelling study.
     Lancet. 2021 Oct 27. pii: S0140-6736(21)02276.
     PubMed     Abstract available
     
     
     
167. USHER AD
     Vaccine shortages prompt changes to COVAX strategy.
     Lancet. 2021;398:1474.
     PubMed    
     
     
     
168. HILLSON K, Clemens SC, Madhi SA, Voysey M, et al
     Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination.
     Lancet. 2021 Oct 21. pii: S0140-6736(21)02282.
     PubMed    
     
     
     
169. SAMARASEKERA U
     Cautious optimism for malaria vaccine roll-out.
     Lancet. 2021;398:1394.
     PubMed    
     
     
     
170. SAAG MS
     Developing COVID-19 vaccine policy in increments.
     Lancet. 2021;398:1382-1383.
     PubMed    
     
     
     
171. THE LANCET
     Malaria vaccine approval: a step change for global health.
     Lancet. 2021;398:1381.
     PubMed    
     
     
     
172. PRENDECKI M, Thomson T, Clarke CL, Martin P, et al
     Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients.
     Lancet. 2021 Oct 4. pii: S0140-6736(21)02096.
     PubMed    
     
     
     
173. TARTOF SY, Slezak JM, Fischer H, Hong V, et al
     Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
     Lancet. 2021 Oct 4. pii: S0140-6736(21)02183.
     PubMed     Abstract available
     
     
     September 2021
174. THE LANCET
     COVID-19: learning as an interdependent world.
     Lancet. 2021;398:1105.
     PubMed    
     
     
     
175. LANE R
     Gagandeep Kang: helping to shape a healthier India.
     Lancet. 2021;398:947.
     PubMed    
     
     
     
176. ALIBERTI S, Dela Cruz CS, Amati F, Sotgiu G, et al
     Community-acquired pneumonia.
     Lancet. 2021;398:906-919.
     PubMed     Abstract available
     
     
     
177. FLAXMAN A, Marchevsky NG, Jenkin D, Aboagye J, et al
     Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).
     Lancet. 2021 Sep 1. pii: S0140-6736(21)01699.
     PubMed     Abstract available
     
     
     August 2021
178. USHER AD
     Health leaders criticise limited ACT-A review.
     Lancet. 2021;398:650-651.
     PubMed    
     
     
     July 2021
179. KICKBUSCH I, Leung GM, Shattock RJ
     Learning from crisis: building resilient systems to combat future pandemics.
     Lancet. 2021;398:e2-e6.
     PubMed    
     
     
     June 2021
180. DANIELS JP
     Colombians protest over inequities and health care.
     Lancet. 2021;397:2454.
     PubMed    
     
     
     
181. USHER AD
     A beautiful idea: how COVAX has fallen short.
     Lancet. 2021;397:2322-2325.
     PubMed    
     
     
     
182. USHER AD
     ACT Accelerator strains donors' aid budgets.
     Lancet. 2021;397:2137.
     PubMed    
     
     
     May 2021
183. SAXENA SG, Godfrey T
     Catalysing needed change for health systems in the USA.
     Lancet. 2021;397:1705-1706.
     PubMed    
     
     
     
184. REINHART E, Dawes D, Maybank A
     Structural medicine: towards an economy of care.
     Lancet. 2021;397:1691-1693.
     PubMed    
     
     
     March 2021
185. THE LANCET
     Myanmar's democracy and health on life support.
     Lancet. 2021;397:1035.
     PubMed    
     
     
     
186. DEVI S
     Health in Syria: a decade of conflict.
     Lancet. 2021;397:955-956.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.